Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies

Peritoneal cancers present significant clinical challenges with poor prognosis. Understanding the role of cancer cell metabolism and cancer-promoting metabolites in peritoneal cancers can provide new insights into the mechanisms that drive tumor progression and can identify novel therapeutic targets...

Full description

Saved in:
Bibliographic Details
Published in:Metabolites 2023-04, Vol.13 (5), p.618
Main Authors: Nadhan, Revathy, Kashyap, Srishti, Ha, Ji Hee, Jayaraman, Muralidharan, Song, Yong Sang, Isidoro, Ciro, Dhanasekaran, Danny N
Format: Article
Language:English
Subjects:
Abdomen
Angiogenesis
Biomarkers
Biosynthesis
Cancer
cancer metabolism
Care and treatment
Cell proliferation
Dehydrogenases
Digestive system cancer
Enzymes
Glucose
Health aspects
Medical prognosis
Mesothelioma
Metabolism
metabolite
Metabolites
metabolome
Metabolomics
Metastasis
Mutation
Oncology, Experimental
oncometabolite
Ovaries
Pathogenesis
Patients
Peritoneum
Prognosis
Review
Sphingosine 1-phosphate
Therapeutic applications
Therapeutic targets
tumor microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peritoneal cancers present significant clinical challenges with poor prognosis. Understanding the role of cancer cell metabolism and cancer-promoting metabolites in peritoneal cancers can provide new insights into the mechanisms that drive tumor progression and can identify novel therapeutic targets and biomarkers for early detection, prognosis, and treatment response. Cancer cells dynamically reprogram their metabolism to facilitate tumor growth and overcome metabolic stress, with cancer-promoting metabolites such as kynurenines, lactate, and sphingosine-1-phosphate promoting cell proliferation, angiogenesis, and immune evasion. Targeting cancer-promoting metabolites could also lead to the development of effective combinatorial and adjuvant therapies involving metabolic inhibitors for the treatment of peritoneal cancers. With the observed metabolomic heterogeneity in cancer patients, defining peritoneal cancer metabolome and cancer-promoting metabolites holds great promise for improving outcomes for patients with peritoneal tumors and advancing the field of precision cancer medicine. This review provides an overview of the metabolic signatures of peritoneal cancer cells, explores the role of cancer-promoting metabolites as potential therapeutic targets, and discusses the implications for advancing precision cancer medicine in peritoneal cancers.
ISSN:2218-1989
2218-1989
DOI:10.3390/metabo13050618